The regions of economic well-being in Italy and SpainMURIAS, P; NOVELLO, S; MARTÍNEZ, F et al.Regional studies. 2012, Vol 46, Num 6, pp 793-816, issn 0034-3404, 24 p.Article

Chemo-radiotherapy in lung cancer : state of the art with focus on the elderly populationMANTOVANI, C; NOVELLO, S; RAGONA, R et al.Annals of oncology. 2006, Vol 17, issn 0923-7534, ii61-ii63, SUP2Conference Paper

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancerMONNERAT, C; HENRIKSSON, R; LE CHEVALIER, T et al.Annals of oncology. 2004, Vol 15, Num 2, pp 316-323, issn 0923-7534, 8 p.Article

Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acidVADHAN-RAJ, S; VON MOOS, R; FENG, A et al.Annals of oncology. 2012, Vol 23, Num 12, pp 3046-3051, issn 0923-7534, 6 p.Article

Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/ gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine aloneNOVELLO, S; BRUZZI, P; MAZZANTI, P et al.Annals of oncology. 2007, Vol 18, Num 5, pp 903-908, issn 0923-7534, 6 p.Article

A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapyCAPPUZZO, F; NOVELLO, S; MARINI, L et al.Lung cancer. 2006, Vol 52, Num 3, pp 319-325, issn 0169-5002, 7 p.Article

Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in ItalyNOVELLO, S; KIELHORN, A; RINALDI, M et al.Lung cancer. 2005, Vol 48, Num 3, pp 379-387, issn 0169-5002, 9 p.Article

Is there a standard strategy in the management of locally advanced non-small cell lung cancer?NOVELLO, S; LE CHEVALIER, T.Lung cancer. 2001, Vol 34, pp S9-S14, issn 0169-5002, SUP4Conference Paper

A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancerNOVELLO, S; BESSE, B; CARCERENY, E et al.Annals of oncology. 2014, Vol 25, Num 11, pp 2156-2162, issn 0923-7534, 7 p.Article

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysisBRIA, E; MILELLA, M; GIANNARELLI, D et al.Annals of oncology. 2011, Vol 22, Num 10, pp 2277-2285, issn 0923-7534, 9 p.Article

Pre-treatment levels of circulating free IGF-I identify NSCLC patients who derive clinical benefit from figitumumabGUALBERTO, A; HIXON, M. L; POLLAK, M. N et al.British journal of cancer. 2011, Vol 104, Num 1, pp 68-74, issn 0007-0920, 7 p.Article

Treatment of advanced non-small cell lung cancerDE PETRIS, L; CRINO, L; SCAGLIOTTI, G. V et al.Annals of oncology. 2006, Vol 17, issn 0923-7534, ii36-ii41, SUP2Conference Paper

State of the art in mesotheliomaSCAGLIOTTI, G. V; NOVELLO, S.Annals of oncology. 2005, Vol 16, pp ii240-ii245, issn 0923-7534, SUP2Conference Paper

Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancerSELVAGGI, G; NOVELLO, S; TORRI, V et al.Annals of oncology. 2004, Vol 15, Num 1, pp 28-32, issn 0923-7534, 5 p.Article

A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels : A phase II randomized trialRINALDI, M; CRINO, L; NOVELLO, S et al.Annals of oncology. 2000, Vol 11, Num 10, pp 1295-1300, issn 0923-7534Article

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancerKERR, K. M; BUBENDORF, L; EDELMAN, M. J et al.Annals of oncology. 2014, Vol 25, Num 9, pp 1681-1690, issn 0923-7534, 10 p.Article

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerSHAW, A. T; VARGHESE, A. M; YEAP, B. Y et al.Annals of oncology. 2013, Vol 24, Num 1, pp 59-66, issn 0923-7534, 8 p.Article

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancerCULLEN, M. H; ZATLOUKAL, P; SÖRENSON, S et al.Annals of oncology. 2008, Vol 19, Num 5, pp 939-945, issn 0923-7534, 7 p.Article

Women and lung cancerNOVELLO, S; BALDINI, E.Annals of oncology. 2006, Vol 17, issn 0923-7534, ii79-ii82, SUP2Conference Paper

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancerCAPPUZZO, F; NOVELLO, S; MARINI, L et al.British journal of cancer. 2005, Vol 93, Num 1, pp 29-34, issn 0007-0920, 6 p.Article

Role of erythropoietin in the treatment of lung cancer associated anaemiaSCAGLIOTTI, G. V; NOVELLO, S.Lung cancer. 2001, Vol 34, pp S91-S94, issn 0169-5002, SUP4Conference Paper

Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancerSCAGLIOTTI, G. V; CRINO, L; TONATO, M et al.Lung cancer. 1999, Vol 25, Num 1, pp 39-46, issn 0169-5002Article

Gemcitabine as second-line treatment for advanced non-small-cell lung cancer : A phase II trialCRINO, L; MOSCONI, A. M; DE MARINIS, F et al.Journal of clinical oncology. 1999, Vol 17, Num 7, pp 2081-2085, issn 0732-183XArticle